• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Organic phosphonic acids and derivatives Organic phosphonic acids

Fosmidomycin (CAS No: 66508-53-0) - A Comprehensive Overview in Modern Chemical Biology and Medicinal Chemistry

Fosmidomycin, chemically designated as (2S,3S,4R,5R)-4-(4-hydroxyphenyl)-2,3-dihydroxy-5-methyl-oxo-1-azabicyclo[3.1.0]hexane-3-carboxylic acid, is a naturally occurring compound with significant implications in the fields of chemical biology and medicinal chemistry. Its unique structural framework and biological activities have positioned it as a cornerstone in the development of novel therapeutic agents, particularly against bacterial infections resistant to conventional antibiotics.

The molecular structure of Fosmidomycin (CAS No: 66508-53-0) features a complex bicyclic system with multiple stereocenters, making it a challenging yet fascinating subject of study. This intricate architecture contributes to its potent inhibitory effects on bacterial enzymes, specifically targeting the phosphoglycerate dehydrogenase (PGDH) enzyme. PGDH is a crucial enzyme in the bacterial glycolysis pathway, responsible for converting 1,3-bisphosphoglycerate into 3-phosphoglycerate. By inhibiting this enzyme, Fosmidomycin effectively disrupts bacterial energy metabolism, leading to growth inhibition and cell death.

Recent advancements in synthetic chemistry have enabled the efficient production and modification of Fosmidomycin, opening new avenues for drug development. Researchers have explored various derivatives of this compound to enhance its pharmacological properties, including improved solubility, bioavailability, and reduced toxicity. These modifications have not only expanded the therapeutic potential of Fosmidomycin but also provided valuable insights into its mechanism of action.

The pharmacological profile of Fosmidomycin has been extensively studied in both preclinical and clinical settings. Notably, its broad-spectrum activity against Gram-positive and Gram-negative bacteria has made it a promising candidate for treating multidrug-resistant infections. Clinical trials have demonstrated its efficacy in treating urinary tract infections and other bacterial infections caused by pathogens such as *E. coli* and *K. pneumoniae*. The compound's ability to overcome antibiotic resistance mechanisms has garnered significant attention from the medical community.

In addition to its antimicrobial properties, Fosmidomycin has shown potential in other therapeutic areas. Studies have explored its role in inhibiting viral replication and preventing the formation of biofilms, which are resistant to conventional antibiotics. These findings highlight the multifaceted applications of Fosmidomycin in addressing various infectious diseases.

The synthesis of Fosmidomycin (CAS No: 66508-53-0) involves a multi-step process that requires precise control over reaction conditions and stereochemistry. Advances in biocatalysis and enzymatic engineering have facilitated the production of this compound through microbial fermentation processes. These biotechnological approaches have not only improved the yield and purity of Fosmidomycin but also reduced the environmental impact associated with traditional synthetic methods.

The development of novel derivatives of Fosmidomycin has been driven by a deeper understanding of its interaction with target enzymes and receptors. Computational modeling and structure-based drug design techniques have played a pivotal role in identifying key structural features that contribute to its biological activity. These insights have guided the design of analogs with enhanced potency and selectivity.

The future prospects for Fosmidomycin are promising, with ongoing research focusing on expanding its therapeutic applications and improving its pharmacokinetic properties. Collaborative efforts between academic institutions, pharmaceutical companies, and regulatory agencies are essential to translate these findings into clinical practice. The continued exploration of this compound holds great potential for addressing emerging infectious diseases and improving global health outcomes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)